View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
May 8, 2017

Regeneron and Inovio to conduct Phase Ib/IIa combination trial to treat GBM

Regeneron Pharmaceuticals has entered a clinical study agreement with Inovio Pharmaceuticals to conduct its Phase Ib/IIa clinical trial of REGN2810 in combination with INO-5401 and INO-9012 to treat patients with newly diagnosed glioblastoma multiforme (GBM).

Regeneron Pharmaceuticals has entered a clinical study agreement with Inovio Pharmaceuticals to conduct its Phase Ib/IIa clinical trial of REGN2810 in combination with INO-5401 and INO-9012 to treat patients with newly diagnosed glioblastoma multiforme (GBM).

REGN2810 is a PD-1 inhibitor, while Inovio's INO-9012 is an immune activator that encodes IL-12 and INO-5401 is a T-cell activating immunotherapy that encodes various antigens.

Set to be commenced in the coming months, the open-label Phase Ib/IIa trial will assess the safety and efficacy of the combination in up to 50 subjects at 30 US clinical centres.

Regeneron translation sciences and oncology vice-president Israel Lowy said: "Regeneron's approach to oncology includes evaluating the combination of innovative therapies that act on diverse pathways and targets.

"Regeneron's approach to oncology includes evaluating the combination of innovative therapies that act on diverse pathways and targets."

"Using our PD-1 inhibitor as a therapeutic backbone alongside Inovio's T-cell-generating therapies offers a new path for exploration and heightens the potential to develop new, desperately needed treatment options for patients."

The primary endpoints of the trial are safety and tolerability, while the immunological impact, progression-free survival and overall survival will also be examined during the treatment period.

Inovio president and chief executive officer Joseph Kim said: "This step with INO-5401 is very important for us in 2017, as we believe INO-5401 has the potential to be a powerful cancer immunotherapeutic in combination with promising checkpoint inhibitors such as Regeneron's REGN2810, and we look forward to investigating its potential for GBM and multiple other challenging cancers."

Under the clinical study agreement, Inovio will conduct and fund the trial with mutually agreed design, while Regeneron will supply REGN2810, which is currently being developed in partnership with Sanofi.

Regeneron and Inovio will jointly perform the immunological analyses related to the trial.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena